Kiltearn Partners LLP Has $4.86 Million Stock Position in Solventum Co. (NYSE:SOLV)

Kiltearn Partners LLP grew its stake in Solventum Co. (NYSE:SOLV - Free Report) by 80.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 73,500 shares of the company's stock after buying an additional 32,800 shares during the period. Kiltearn Partners LLP's holdings in Solventum were worth $4,855,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. lifted its position in Solventum by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 16,266,893 shares of the company's stock worth $1,074,591,000 after acquiring an additional 75,631 shares during the last quarter. State Street Corp lifted its position in shares of Solventum by 3.1% during the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company's stock worth $425,818,000 after purchasing an additional 185,938 shares during the last quarter. Geode Capital Management LLC boosted its stake in Solventum by 4.0% during the 3rd quarter. Geode Capital Management LLC now owns 3,347,719 shares of the company's stock valued at $232,608,000 after purchasing an additional 128,317 shares during the period. Norges Bank acquired a new stake in Solventum in the 4th quarter valued at approximately $203,740,000. Finally, Hotchkis & Wiley Capital Management LLC bought a new position in Solventum in the 3rd quarter worth approximately $125,488,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on SOLV shares. The Goldman Sachs Group raised their price objective on shares of Solventum from $63.00 to $71.00 and gave the stock a "sell" rating in a research note on Monday, March 3rd. Wells Fargo & Company boosted their price objective on shares of Solventum from $73.00 to $75.00 and gave the stock an "equal weight" rating in a report on Friday, February 28th. Mizuho upped their price objective on shares of Solventum from $70.00 to $82.00 and gave the company a "neutral" rating in a research report on Monday, March 3rd. Bank of America lifted their target price on Solventum from $80.00 to $85.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 26th. Finally, Piper Sandler upped their price target on Solventum from $75.00 to $84.00 and gave the company a "neutral" rating in a report on Friday, February 28th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $79.86.

Remove Ads

Solventum Price Performance

NYSE:SOLV traded up $0.13 during trading hours on Tuesday, reaching $76.17. The company had a trading volume of 270,427 shares, compared to its average volume of 1,089,055. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The stock has a 50-day moving average of $75.56 and a two-hundred day moving average of $71.92. Solventum Co. has a one year low of $47.16 and a one year high of $85.92. The firm has a market capitalization of $13.18 billion and a PE ratio of 27.70.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.